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A cross-sectional study and theoretical consideration
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∗
, Amir Emamifar, MDa, Rikke A. Andreasen, MDa,
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Abstract
Disease Activity Score in 28 joints (DAS28) is commonly used to evaluate disease activity of rheumatoid arthritis (RA) and is a guide to
treatment decision.
The aim of this study was to evaluate the impact of lower reporting limit for C-reactive protein (CRP), with respect to intraindividual
biological variability, on the calculation of DAS28 and subsequent patient classiﬁcation.
This study consists of 2 sections: a theoretical consideration discussing the performance of CRP in calculating DAS28 taking
intraindividual biological variation and lower reporting limit for CRP into account and a cross-sectional study of RA patients applying
our theoretical results. Therefore, we calculated DAS28 twice, with the actual CRP values and CRP=9mg/L, the latter to elucidate
the positive effects of reducing the lower reporting limit of CRP from <10 to <3mg/L.
Lower-reporting limit of <10mg/L leads to overestimate DAS28. However, reducing lower reporting limit for CRP to <3mg/L
results in optimizing DAS28 calculation. Further lowering of reporting limit for CRP to <3mg/L does not increase the precision of
DAS28 owing to the relatively large intraindividual biological variation.
Five hundred twelve patients were included. There was a signiﬁcant difference between recalculated and patients DAS28 (P<
0.001). One hundred nine patients had DAS28 deviation (compatible to remission to low: 66, low to moderate: 39. and moderate to
high: 4).
Owing to signiﬁcant impact of intraindividual biologic variation on DAS28 and patient classiﬁcation, special attention should be paid
to calculate DAS28 when CRP values are within normal range. Furthermore, we conclude that results of different studies evaluating
DAS28 and treatment response are not comparable if the reporting limits of CRP are unknown.
Abbreviations: anti-CCP= anti-cyclic citrullinated peptide, CRP=C-reactive protein, DAS28-CRP=Disease Activity Score in 28
joints-C- reactive protein, DAS28-ESR = Disease Activity Score in 28 joints-erythrocyte sedimentation rate, DMARDs = disease-
modifying antirheumatic drugs, ESR = erythrocyte sedimentation rate, hs-CRP = high-sensitivity CRP, IgM RF = IgM rheumatoid
factor, PGA= Patient Global Assessment, RA= rheumatoid arthritis, SD= standard deviation, SJ= swollen joints, TJ= tender joints.
Keywords: C-reactive protein, DAS28, intraindividual biological variation, reporting limit, rheumatoid arthritis
1. Introduction
Rheumatoid arthritis (RA) is a chronic disease with a prevalence
of 0.5% to 1% of the general population. Pain, swelling, redness,
fatigue, decreased functional capacity and prolonged stiffness
following rest are the most frequent symptoms. It has been
generally accepted that RA should be treated instantly to improve
clinical outcome and prevent further joint destruction. In order to
achieve this goal, various composite indices have been proposed
to monitor RA disease activity and effects of treatment [1–3].
Disease activity score (DAS) is a scoring system that is commonly
used in daily clinical practice to evaluate disease activity ofRA.[4] It
was ﬁrstly derived from a set of 4 variables including: number of
painful joints calculatedwith the Ritchie Articular Index, 44-joint-
count for swelling, erythrocyte sedimentation rate (ESR), and
general health or patient’s global assessment (PGA) of disease
activity on a 100-mm visual analog scale (VAS). Subsequently,
DAS28 was developed and validated.[3] The DAS28 score is
calculated from 4 components including: tender joints (TJ)(range
0–28), swollen joints (SJ) (range 0–28), PGA (range 0–100),
and laboratory values of ESR or C-reactive protein (CRP).[5]
DAS28-CRP and DAS28-ESR can be calculated using the
following, closely related formulas: DAS28-CRP=0.56∗
p
(TJ)+
0.28∗
p
(SJ)+0.36∗ln(CRP+1)+0.014∗PGA+0.96 and DAS28-
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ESR=0.56∗
p
(TJ)+0.28∗
p
(SJ)+0.70∗ln(ESR)+0.014∗PGA. In
the authors’ country, Denmark, DAS28-CRP is generally used
to measure disease activity. DAS28-CRP ranges from 0.96 to
maximum of 9.4 (the latter if CRP is 100mg/L). A DAS28 value of
>5.1 indicates highdisease activity, 3.2<DAS285.1 andDAS28
3.2aredeﬁnedasmoderate and lowdisease activity. Patientsmay
be considered to be in remission phase if DAS28 is <2.6.[6]
CRP is an acute-phase reactant that increases within 4 to 6
hours of inﬂammation or acute tissue injury.[7] It can be tested by
different assays with different measuring ranges. Previously,
lower measuring limits of 3 to 10mg/L were common, whereas
during recent years, analytical methods optimized to measure
results as low as 0.1mg/L have become widely used, often called
high-sensitivity CRP (hs-CRP) methods. The threshold for
reporting of CRP has in most hospitals been declining over time
at a varying speed and with variations from laboratory to
laboratory. The potential clinical beneﬁts of measuring CRP in
the normal range using hs-CRP methods have been evaluated
broadly in cardiovascular disease,[8,9] whereas the role of hs-CRP
in rheumatoid diseases has been investigated to much lesser
extent.
The intraindividual biological variation (CV-within) of CRP in
healthy subjects has been estimated to 42% to 76%, whereas
analytical variation is <10%.[10,11] Furthermore, near lower
reporting limit, the intraindividual biological variation of CRP in
RA patients is unknown; however, it is probably higher than in
healthy subjects with identical mean CRP level. Even if it should
be lower than for healthy subjects, it is still a factor of variation
with major inﬂuence on the DAS28. We showed previously that
biological variation of CRP might cause signiﬁcant ﬂuctuation in
the DAS28 score with consequence on patient classiﬁcation and
subsequent treatment plan.[12]
With respect to DAS28 and RA, reporting limit for CRP
becomes more important, as CRP has a direct effect on
calculating DAS28, patient classiﬁcation, and treatment deci-
sions. The objective of present study is to investigate the impact of
lower reporting limit for CRP, taking intraindividual biological
variation into account, to calculate DAS28 and subsequent
patient classiﬁcation both theoretically and clinically. In our
hospital, CRP results <10mg/L were reported as <10mg/L until
25th February 2013. In the period from February 25, 2013 to
March 17, 2015, results were reported down to 3mg/L and lower
results as <3mg/L. Since March 17, 2015 results of CRP are
reported down to 0.6mg/L.
2. Materials and method
The present study consists of 2 sections: the ﬁrst section is a
theoretical consideration discussing the performance of CRP in
calculating DAS28 with regard to intraindividual biological
variation and the reporting limit for CRP (Part A and B); the
second section is a cross-sectional study to evaluate the clinical
signiﬁcance of the lower reporting limit for CRP in all our RA
patients seen until April 2015.
2.1. Theoretical consideration
2.1.1. Part A. The aim of this study was to evaluate the isolated
performance of CRP values to calculate DAS28, in particular
when CRP is<10mg/L. We calculated DAS28 considering single
parameter (CRP) with holding other parameters zero by using the
following formula: DAS28=0.56∗
p
(TJ) + 0.28∗
p
(SJ) + 0.36∗ln
(actual CRP value+1) + 0.014∗PGA + 0.96. Therefore, different
values of CRP ranging from 1 to 100mg/L plus TJ=0, SJ=0, and
PGA=0 were entered into the formula to perform the calculation
(Fig. 1A).
2.1.2. Part B.With a lower reporting limit of CRP<10mg/L, the
real CRP values could be all ﬁgures between 9 and 0 and with a
lower reporting limit of CRP <3mg/L, between 2 and 0 as well.
As a result, we introduced the following example with the lower
limit of <10mg/L and 3mg/L taking into account the intra-
individual biological variation.
Different values of DAS28 based on various values of
CRP (0–40mg/L) and constant values of TJ (TJ=3), SJ (SJ=
1), and PGA (PGA=34) were calculated using the above-
mentioned DAS28 formula, as well as upper and lower limits
of DAS28. Thus, DAS28 were calculated 5 times as described
below:
1. With CRP values ranging from 1 to 40mg/L without limit.
2. With CRP values with lower reporting limit of 3mg/L ranging
from 3 to 40mg/L.
3. With CRP values with lower reporting limit of 10mg/L
ranging from 10 to 40mg/L.
4. With upper limit of CRP based on biological variation. The
upper limit values of CRP were calculated as CRP plus CRP
multiplied by the lowest percentage (42%) of the intra-
individual biological variation previously described, multi-
plied with 1.96 (twice the standards deviation [SDs]) (CRP+
[CRP0.8]).
5. With lower limit of CRP values based on biological variation.
The lower limit values of CRP were calculated as CRP minus
Figure 1. (A) The relation between DAS28 and CRP, when CRP ranging from 0
to 100 and other parameters were held constant (Tender joint=0, Swollen
joint=0, and patient global assessment=0). (B) Dependency of DAS28 to CRP
(theoretical consideration). Tender joint: 3, Swollen joint: 1, and patient global
assessment: 34. CV-within: intraindividual biological variation. DAS28=
Disease Activity Score in 28 joints, CRP=C-reactive protein.
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CRP multiplied by the lowest percentage (42%) of the
intraindividual biological variation previously described,
multiplied with 1.96 (twice the SD) (CRP [CRP0.8]).
A line chart was drawn to show the results of different DAS28
values (Fig. 1B).
2.2. Cross-sectional study
The Danish Danbio registry provides national data on the disease
course of patients with inﬂammatory rheumatic disease including
RA via a personal identiﬁcation number. It was established in
2000 and is approved by the Danish Data Registry (j. nr.
2007–58–0014 and j.nr. 2007–58–0006) and National Board of
Health (j. nr. 7–201–03–12/1). Since 2007, all newly diagnosed
RA patients in Denmark should be registered in Danbio.
Variables in Danbio are categorized into baseline and longitu-
dinal.[13] At our rheumatology outpatient clinic, these variables
for our entire RA patients are entered into Danbio at every
consultation.
2.3. Setting, design, and ethics committee approval
This was a-cross sectional, registry-based, single center study. All
parts of study were performed at the rheumatology outpatient
clinic.
Ethical approval was obtained from Danish Data Protection
Agency (ﬁle no.15/25403).
2.4. Participants
All patients diagnosed with RA are registered in the local part
of Danbio by rheumatologists during outpatient visits. In
April 2015, data for our entire RA patients (n=876) were
extracted from Danbio. Since 2010, diagnosis of RA was made
according to the new 2010 American College of Rheumatology
(ACR)/European League against Rheumatism (EULAR) criteria
for RA.
Inclusion criteria were as follows: patients who were registered
in the rheumatology outpatient clinic, age ≥18 years, CRP results
were reported after 25th Feb 2013 since lower reporting limit was
set to 3mg/L and then 0.6mg/L. Patients who passed away or
were referred to the other departments were also included.
Patients with incomplete Danbio registration were excluded from
the study.
After obtaining all data from included patients, DAS28 was
calculated for each individual patient twice, ﬁrst with patients
actual CRP and hereafter with a constant value of CRP=9mg/L
to illustrate the consequences of the lower reporting limit of CRP
for the DAS28 calculation. Subsequently, we assessed whether
new DAS28 values caused any changes in the patients
classiﬁcation.
2.5. Data collection and variables
Patients’ demographic data including age, sex, and disease
characteristics (TJ, SJ, PGA, DAS28, CRP, IgM rheumatoid
factor [IgM RF] [normal range: <15IU/mL], and anti-cyclic
citrullinated peptide [anti-CCP] [normal range: <20EU/mL])
were extracted from Danbio. DAS28 was calculated using the
following formula: DAS28=0.56∗
p
(TJ) + 0.28∗
p
(SJ) + 0.36∗ln
(CRP+1) + 0.014∗PGA + 0.96 with actual CRP initially and
CRP=9mg/L thereafter. To measure PGA, 100-mm visual
analogue scale technique was used.
2.6. Statistical analysis
All statistical analyses were performed by Microsoft Excel 2010.
Continuous data are presented as mean±SD, categorical data as
frequencies and respective percentages.We used following ranges
to indicate the patients’ disease activity: high disease activity
DAS28 >5.1, moderate disease activity 3.2 < DAS28  5.1, low
disease activity DAS28 3.2, and remission phase compatible
with DAS28 <2.6. P values were calculated using the Student t
test and considered as signiﬁcant if P<0.05. Number of patients
with changes in disease activity classiﬁcation has been shown
with bar chart. In case of missing data, we used pairwise deletion
to keep as many cases as possible for each analysis.
3. Results
3.1. Theoretical consideration
3.1.1. Part A. Calculating DAS28 holding TJ, SJ, and PGA zero
and increasing CRP from 0 to 100mg/L shows that there is a
steep increase in DAS28 specially when CRP <10mg/L and to a
lesser extent when CRP=10 to 20mg/L. The area of CRP
between 0 and 10mg/L is of particular interest in this article
because of the lower reporting limit for CRP within this range.
The steepness of the curve is because of the logarithmic function
of CRP when calculating DAS28 (ln [CRP+1]) (Fig. 1A).
3.1.2. Part B. Figure 1B illustrates the DAS28 with varying CRP
levels, whereas other contributors to DAS28 (TJ, SJ, and PGA)
are held constant at arbitrarily chosen values. Furthermore, lines
of CRP±1.96CV-within are shown. A single CRP result of an
individual person will with a probability of 95% be within these
limits. In case of lower reporting limit of 10mg/L and interpreting
all results of <10mg/L as 9mg/L results is shown as the curve
marked by triangles, which cross CRP + 2 × CV-within around 6
mg/L, meaning that DAS28 will be overestimated, more than
could explained by intraindividual biological variation, when
CRP is really <5mg/L.
If lower reporting limit was 3mg/L and all results of <3mg/L
were interpreted as 2mg/L, results are given as the curve marked
by diamonds, which slightly increases CRP + 2 × CV-within at 1
mg/L, meaning that DAS28 will be slightly overestimated, more
than explained by intraindividual biological variation when CRP
really is 1mg/L.
Lowering of reporting limit for CRP to <3mg/L cannot be
expected to contribute to the precision of DAS28 owing to the
relatively large intraindividual biological variation making a
huge impact on DAS28.
3.2. Cross-sectional study
A total of 876 patients with diagnosis of RAwere registered in the
local part of Danbio. Three hundred sixty-four patients were
excluded from the study. Reasons of exclusion were: incomplete
Danbio registration (n=108) or lack of CRP results and CRP
results were reported before February 25, 2013. Of 512 included
patients, 332 (65%) were female and the mean of age was 65.5±
14.0 (mean±SD). Demographic and disease characteristics are
summarized in Table 1.
The mean value of recalculated DAS28 was 2.8±0.9 (mean±
SD). There was a statistically signiﬁcant difference between
patients’DAS28 (with actual CRP) and recalculated DAS28 with
CRP=9mg/L (P<0.001).
Recalculating DAS28 with CRP=9mg/L resulted in deviation
of patient classiﬁcation from compatible with remission to low
Hansen et al. Medicine (2017) 96:1 www.md-journal.com
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(66 patients), low to moderate (39 patients), and moderate to
high (4 patients) (a total of 109 patients) (Fig. 2), illustrating that
a reporting limit of <10mg/L combined with interpretation of
results reported as <10mg/L as 9mg/L would have resulted in a
misclassiﬁcation of 14% of the patients in an upward direction.
4. Discussion
It has been generally accepted that RA should be controlled
instantly. Regular clinical evaluation of RA with the aim of
different scoring systems including DAS28 helps clinicians to
reach the optimal control. DAS28 score is a guide to start,
change, or to stop treatment with disease-modifying antirheu-
matic drugs (DMARDs). Therefore, it should be calculated
precisely, whereas miscalculation of DAS28 score results in
incorrect patient classiﬁcation and treatment plan.[12] The key
result of this study can be summarized as follows: lower reporting
limit of <10mg/L in combination with interpretation of <10mg/
L as 9mg/L, leads to inaccurate patient classiﬁcation in a great
number of patients (109/512 in this study) with possibly
consequences on treatment decision and this is particularly
relevant when initiating of biologics has been considered because
of considerable medical expenses; reducing lower reporting limit
for CRP to <3mg/L will optimize the correct patient classiﬁca-
tion; and there is no further gain from calculating DAS28 with
high sensitivity assay of CRP because of high intraindividual
variability of CRP. Considering real CRP values between 0 and 9,
there is a large impact on ﬁnal DAS28 score if CRP values are
reported as<10mg/L with a direct effect on patient classiﬁcation
as well as treatment decision. However, reducing the reporting
limit for CRP values to <3mg/L will minimize the impact on
DAS28 score and patient classiﬁcation. This impact is greatest,
when CRP values are <10mg/L because of the logarithmic
function of CRP in the formula (0.36∗ln [CRP+1]). These results
were also applicable in the RA population included in the study,
as a total of 109 (21.3%) patients had a disease activity deviation
from compatible to remission to low, low to moderate, or
moderate to high, when DAS 28 was calculated using CRP=9
mg/L, comparing with actual values of CRP, if the reporting limit
has not been reduced to <3mg/L.
During the last decades, high sensitive assays have been
developed to detect lower CRP concentration (down to <0.1mg/
L) than by earlier low-sensitivity laboratory techniques.[14] These
assays are commonly used in cardiovascular disease risk
assessment and to a lesser extent in other clinical areas especially
malignant diseases.[15,16] Based on our theoretical consideration,
a lower reporting limit for CRP <3mg/L will result in lower
DAS28 scores; however, these will still be challenged by high
intraindividual variability of CRP and cannot be expected to
increase the clinical usefulness of DAS28. Thus, for the individual
patient, neither risk assessment in various diseases nor DAS28
calculation are optimized using hs-CRPmeasurements because of
the intraindividual biologic variation of CRP. Consequently, the
authors do not think that it is necessary to implement high-
sensitivity CRP assays for calculating DAS28. To reduce the
effect of intraindividual biological variation of CRP, DAS28
might be calculated using the average of multiple CRP
measurements in the individual patient taken during a period
of stable disease activity. Theoretically, an average of 4 and 9
consecutive CRP measures reduces the intraindividual biological
variation by half and one-third; however, it is unrealistic in daily
clinical practice.
DAS28, as mentioned above, can be measured by either
applying CRP or ESR values. The formulas are used to calculate
DAS28-ESR and DAS-CRP are very close to each other. The
logarithmic function of ESR and CRP in the formulas causes
great ﬂuctuations, especially in the lower values. Therefore, with
respect to the intraindividual biological variability (around 30%)
and lower reporting limit of ESR (1mm),[17] it is theoretically
feasible to consider similar misinterpretation in the calculation of
DAS28-ESR and further misclassiﬁcation of the patients;
however, it is essential to mention that such an assumption is
not practically relevant because the reporting limit of ESR has not
changed since the establishment of ESR analysis in the 19th
century.[18] However, results of the present study potentially
affect the interpretation of earlier studies’ ﬁndings, where there
was underestimation of disease activity by DAS28-CRP com-
pared to DAS28-ESR, if the lower reporting limit of <10mg/L
was used by the local laboratory.[19,20]
RA response to treatment has been improved extensively since
the introduction of DMARDs.[21,22] Although we conﬁrm this, it
is reasonable to consider the impact of reporting limit of CRP on
the calculation of DAS28 and evaluating response to treatment,
since reporting lower values of CRP by new methods or reducing
the lower limit of CRP will cause lower DAS28 implying better
response to treatment. Therefore, the authors conclude that the
results of different studies evaluating different treatment
modalities should not be compared, if the reporting limits of
CRP are unknown.
Figure 2. Changes in patients’ disease activity when DAS28 calculated with
CRP=9mg/L. DAS28=Disease Activity Score in 28 joints, CRP=C-reactive
protein.
Table 1
Characteristic of Patients.
N=512
Age, y Mean±SD 65.5±14.0
Sex Male 180 (35%)
Female 332 (65%)
DAS28 Mean±SD 2.4±0.9
Max 6.2
Min 1.0
IgM-RF Positive 286 (56%)
Negative 223 (43%)
No data 3 (1%)
Anti-CCP Positive 251 (49%)
Negative 257 (50%)
No data 4 (1%)
CCP= cyclic citrullinated peptide, DAS28=Disease activity score in 28 joints, RF= rheumatoid factor,
SD= standard deviation.
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The limitation of the present study is that the intraindividual
biological variation of CRP in patients with RA is not known. This
might be lower, higher, or the same as healthy individuals;
however, we have used a rather conservative value (low value) of
CV-within in our calculations. If CV-within actually is higher in
RA, impact onDAS28will be larger and reporting limits as high as
4 or 5mg/Lmight be theoretically acceptable in case of calculation
of DAS28. The results of this study have a high degree of
generalizability owing to a feasible sample size and broad inclusion
criteria and are relevant to all rheumatology departments.
In conclusion, clinicians should be cautious to interpret DAS28
when results of CRP are within normal values, no matter which
reporting limit is used by the local laboratory, as intraindividual
biological variation of CRP might cause a signiﬁcant ﬂuctuation
in the ﬁnal DAS28 leading to inaccurate patient classiﬁcation. It is
always advisable to use >1 CRP result and DAS28 calculation
before classifying any RA patient.
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